HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

S&E In Brief

This article was originally published in The Rose Sheet

Executive Summary

Avon: Revenue rose 14% to $2.5 bil. in Avon's fiscal 2010 first quarter, while earnings dropped 64% to $42.5 mil., New-York-based direct seller reports April 30. Earnings declines were attributed to restructuring costs and the impact of currency devaluation in Venezuela, as predicted (1"The Rose Sheet" Feb. 8, 2010, In Brief). Avon spent $96 mil. on advertising in the quarter - up 23% from the same period last year - as it focused on sales representative recruitment. Its sales force increased by 6% in the quarter, growing in all regions except for China, firm says. North American revenue slipped 2%, negatively impacted by lower average orders and weakness in non-beauty business. Avon "expects results to vary on a quarterly basis" for 2010 as the firm optimizes its product portfolio and "enhances field fundamentals.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel